Lung cancer screening in Brazil: recommendations from the Brazilian Society of Thoracic Surgery, Brazilian Thoracic Association, and Brazilian College of Radiology and Diagnostic Imaging
Authors:
- Luiz Fernando Ferreira PereiraLPLuiz Fernando Ferreira Pereira
- Ricardo Sales Dos SantosRSRicardo Sales Dos Santos
- Daniel Oliveira BonomiDBDaniel Oliveira Bonomi
- Juliana FranceschiniJFJuliana Franceschini
- Ilka Lopes SantoroISIlka Lopes Santoro
- André MiottoAMAndré Miotto
- Thiago Lins Fagundes de SousaTSThiago Lins Fagundes de Sousa
- Rodrigo Caruso ChateRCRodrigo Caruso Chate
- Bruno HochheggerBHBruno Hochhegger
- Artur Gomes NetoANArtur Gomes Neto
- Airton SchneiderASAirton Schneider
- César Augusto de Araújo NetoCNCésar Augusto de Araújo Neto
Open Access
- 27 February 2024
- journal article
- research article
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 50 (1) , e20230233
Abstract
Although lung cancer (LC) is one of the most common and lethal tumors, only 15% of patients are diagnosed at an early stage. Smoking is still responsible for more than 85% of cases. Lung cancer screening (LCS) with low-dose CT (LDCT) reduces LC-related mortality by 20%, and that reduction reaches 38% when LCS by LDCT is combined with smoking cessation. In the last decade, a number of countries have adopted population-based LCS as a public health recommendation. Albeit still incipient, discussion on this topic in Brazil is becoming increasingly broad and necessary. With the aim of increasing knowledge and stimulating debate on LCS, the Brazilian Society of Thoracic Surgery, the Brazilian Thoracic Association, and the Brazilian College of Radiology and Diagnostic Imaging convened a panel of experts to prepare recommendations for LCS in Brazil. The recommendations presented here were based on a narrative review of the literature, with an emphasis on large population-based studies, systematic reviews, and the recommendations of international guidelines, and were developed after extensive discussion by the panel of experts. The following topics were reviewed: reasons for screening; general considerations about smoking; epidemiology of LC; eligibility criteria; incidental findings; granulomatous lesions; probabilistic models; minimum requirements for LDCT; volumetric acquisition; risks of screening; minimum structure and role of the multidisciplinary team; practice according to the Lung CT Screening Reporting and Data System; costs versus benefits of screening; and future perspectives for LCS.Keywords
This publication has 148 references indexed in Scilit:
- Screening for Lung CancerJAMA, 2021
- Screening for Lung Cancer With Low-Dose Computed TomographyJAMA, 2021
- Electronic cigarettes for smoking cessationCochrane Database of Systematic Reviews, 2020
- Antidepressants for smoking cessationCochrane Database of Systematic Reviews, 2020
- WHO Report–Tobacco Use Decreasing Globally, but Not on Track to Meet 2025 TargetJAMA Health Forum, 2020
- Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult SmokersJAMA Oncology, 2019
- Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer ScreeningJAMA, 2016
- Nicotine receptor partial agonists for smoking cessationCochrane Database of Systematic Reviews, 2016
- Pharmacological interventions for smoking cessation: an overview and network meta-analysisCochrane Database of Systematic Reviews, 2013
- Screening by Chest Radiograph and Lung Cancer MortalityJAMA, 2011